fludarabine has been researched along with thiotepa in 72 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (20.83) | 29.6817 |
| 2010's | 32 (44.44) | 24.3611 |
| 2020's | 25 (34.72) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Burckhardt, G; Flörl, S; Hagos, Y; Kühne, A; Marada, VV | 1 |
| Alessandrino, EP; Bernasconi, C; Bernasconi, P; Bonfichi, M; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Pagnucco, G; Varettoni, M | 1 |
| Benedetti, F; Bordignon, C; Bregni, M; Ciceri, F; Corradini, P; Dodero, A; Falda, M; Gianni, AM; Ladetto, M; Lucesole, M; Olivieri, A; Pileri, A; Rambaldi, A; Sajeva, MR; Tarella, C; Tresoldi, M; Voena, C; Zallio, F | 1 |
| Abonour, R; Logan, TF; Nelson, RP | 1 |
| Caenazzo, L; Calore, E; Cesaro, S; De Silvestro, G; Destro, R; Gazzola, MV; Marson, P; Messina, C; Pillon, M; Varotto, S; Zanesco, L | 1 |
| Amin, K; Chen, YH; Cheung, T; Devine, S; Hoffman, R; Jessop, E; Maynard, V; Peace, D; Ravandi, F; Sosman, J; Stock, W; van Besien, K; Vijayakumar, S; Wickrema, A; Yassine, M | 1 |
| Byun, JH; Hong, YS; Kim, CC; Lee, JW; Lee, MA; Min, WS; Park, JN; Roh, SY; Shim, BY; Song, CW | 1 |
| Alessandrino, EP; Bernasconi, P; Caldera, D; Colombo, AA; Lazzarino, M; Malcovati, L; Montanari, F; Troletti, D; Vanelli, L; Varettoni, M | 1 |
| Bernardi, M; Bregni, M; Corradini, P; Deola, S; Fleischhauer, K; Guggiari, E; Lunghi, F; Mazzi, B; Monari, M; Peccatori, J; Pescarollo, A; Re, F; Scaramuzza, S; Servida, P; Setola, E | 1 |
| Arbelaez, JE; Bacigalupo, A; Bregni, M; Carnevalli, E; Corradini, P; Davoli, M; De Fabritiis, P; Di Bartolomeo, P; Locasciulli, A; Majolino, I; Musso, M; Narni, F; Olivieri, A; Pogliani, L; Ruscio, C; Scimè, R; Selleri, C | 1 |
| Allwinn, R; Beske, F; Klingebiel, T; Kriener, S; Lehrnbecher, T; Modrow, S; Schmidt, H; Schwabe, D; Sörensen, J | 1 |
| Bertz, H; Finke, J; Grüllich, C; Müller, CI; Spyridonidis, A | 1 |
| Bernardo, ME; Caocci, G; Comoli, P; Cugno, C; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Merli, P; Piras, E; Vacca, A; Zecca, M | 1 |
| Cano, P; Champlin, RE; Ciurea, SO; de Lima, M; Fernandez-Vina, M; Gajewski, J; Giralt, S; Jones, RB; Kebriaei, P; Korbling, M; McMannis, J; Pesoa, S; Qazilbash, M; Qureshi, S; Rondon, G; Saliba, R; Shpall, EJ; Worth, LL | 1 |
| Fujioka, T; Ikegame, K; Inoue, T; Kaida, K; Kato, R; Kim, EH; Nakata, J; Ogawa, H; Okada, M; Soma, T; Tamaki, H; Taniguchi, K; Yoshihara, S | 1 |
| Cassuto, JP; Cluzeau, T; De Matteis, M; Gratecos, N; Mannone, L; Mounier, N; Raynaud, S; Sirvent, A; Thyss, A; Ticchioni, M | 1 |
| Abraham, A; Kasow, KA; Morales-Tirado, VM; Persons, DA; Riberdy, JM; Shurtleff, SA; Wichlan, D | 1 |
| Bassett, R; Champlin, RE; Chan, KW; Ciurea, SO; Couriel, DR; de Lima, M; Fernandez-Vina, M; Hamerschlak, N; Hosing, CM; Jones, RB; Karduss Aurueta, AJ; Kebriaei, P; McMannis, J; Nieto, Y; Petropoulos, D; Qazilbash, M; Rondon, G; Saliba, RM; Sharma, M; Shpall, EJ; Worth, LL | 1 |
| Anasetti, C; Cooley, S; Curtsinger, J; Defor, T; Devine, S; DiPersio, J; Drobyski, W; Farag, S; Fehniger, TA; Haagenson, M; Miller, J; Porter, D; Waller, EK; Weisdorf, D | 1 |
| Barrenetxea, C; Boluda, JC; de Heredia, CD; Ferrá, C; González, M; Martín, C; Martinez, AM; Sanz, GF; Sanz, J; Sanz, MA; Serrano, D; Solano, C | 1 |
| Bertz, H; Christopoulos, P; Finke, J; Ihorst, G; Marks, R; Wäsch, R | 1 |
| Bernardo, ME; Bertaina, A; Caocci, G; Contoli, B; Giorgiani, G; La Nasa, G; Locatelli, F; Mastronuzzi, A; Pagliara, D; Pinto, RM; Piras, E; Vacca, A; Zecca, M | 1 |
| Bacigalupo, A; Ballerini, F; Bregante, S; Di Grazia, C; Dominietto, A; Geroldi, S; Ghiso, A; Gualandi, F; Lamparelli, T; Luchetti, S; Miglino, M; Raiola, AM; Van Lint, MT; Varaldo, R | 1 |
| Choudhary, D; Gupta, N; Handoo, A; Katewa, S; Kharya, G; Pavecha, P; Setia, R; Sharma, SK | 1 |
| Bertz, H; Christopoulos, P; Finke, J; Marks, R; Schmoor, C; Wäsch, R; Waterhouse, M | 1 |
| Andersson, BS; Bayraktar, UD; Boulad, F; Castro-Malaspina, HR; Champlin, RE; Chen, J; Chiattone, A; de Lima, M; Giralt, S; Jakubowski, AA; Kernan, NA; Maloy, M; O'Reilly, RJ; Papadopoulos, EB; Rondon, G; Saliba, RM | 1 |
| Benesch, M; Brunner-Krainz, M; Lackner, H; Paschke, E; Plecko, B; Raicht, A; Schwinger, W; Seidel, M; Sovinz, P; Sperl, D; Strenger, V; Urban, C | 1 |
| Dinur-Schejter, Y; Erlich, O; Gorelik, N; Krauss, AC; Porat, I; Stein, J; Stepensky, P; Weintraub, M; Yahel, A; Zaidman, I | 1 |
| Angelucci, E; Baronciani, D; Culurgioni, F; Depau, C; Derudas, D; Latte, G; Palmas, A; Tandurella, I; Targhetta, C | 1 |
| Barba, P; Bautista, G; Cabrera, JR; Duarte, R; Esquirol, A; Fores, R; García, I; García-Marco, JA; Heras, I; Marquez-Malaver, FJ; Martino, R; Parody, R; Regidor, C; Rovira, M; Saavedra, S; Sánchez-Ortega, I; Serrano, D; Sierra, J; Vazquez, L | 1 |
| Champagne, C; Farrant, P; Taylor, M | 1 |
| Arcese, W; Barba, P; Esquirol, A; Gayoso, J; Guidi, S; Martino, R; Montesinos, P; Moscardó, F; Parody, R; Picardi, A; Piñana, JL; Sanz, G; Sanz, J; Sanz, MA; Sierra, J; Solano, C; Terol, MJ | 1 |
| Crazzolara, R; Haas, OA; Kager, L; Kropshofer, G; Matthes-Martin, S | 1 |
| Abraham, A; Cluster, A; Delgado, D; Hulbert, ML; Jacobsohn, D; Kukadiya, D; Murray, L; Shenoy, S | 1 |
| Anand, S; Chao, NJ; Corbet, K; Gasparetto, C; Horwitz, ME; Long, GD; Lopez, R; Morris, AK; Rizzieri, DA; Sarantopoulos, S; Sullivan, KM; Sung, AD; Thomas, S | 1 |
| Bruno, B; Chalandon, Y; Charbonnier, A; Coiteux, V; Simon, N; Souchet, L; Taque, S; Vincent, L; Yakoub-Agha, I | 1 |
| Bruce, K; Domm, J; Evans, M; Frangoul, H; Isbell, J | 1 |
| Aljurf, M; Arcese, W; Beohou, E; Bonifazi, F; Bruno, B; Labopin, M; Lanza, F; Mohty, M; Nagler, A; Passweg, J; Pioltelli, P; Santarone, S; Saraceni, F; Savani, BN; Sociè, G; Stepensky, P; Yakoub-Agha, I | 1 |
| Angelucci, E; Arcese, W; Baron, F; Benedetto, B; Blaise, D; Carella, MA; Giannotti, F; Labopin, M; Mohty, M; Nagler, A; Rambaldi, A; Rocha, V; Ruggeri, A; Saccardi, R; Santarone, S; Santasusana, JR; Sanz, J; Shouval, R; Sierra, J | 1 |
| Alessandrino, EP; Bacigalupo, A; Bonifazi, F; Bosi, A; Bregante, S; Bruno, B; Carella, AM; Fanin, R; Finazzi, MC; Mammoliti, S; Masciulli, A; Messina, G; Milone, G; Narni, F; Patriarca, F; Pavoni, C; Rambaldi, A; Russo, D | 1 |
| Basu, O; Döring, M; Ebinger, M; Gruhn, B; Handgretinger, R; Heinzelmann, F; Holzer, U; Lang, P; Paulsen, F; Teltschik, HM; Wegener, D; Weidner, N; Wittig, A; Zips, D | 1 |
| Adaeva, R; Banet, A; Bastos, J; Battipaglia, G; Belhocine, R; Brissot, E; de Wyngaert, ZV; Duléry, R; Giannotti, F; Isnard, F; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Mohty, M; Paviglianiti, A; Rubio, MT; Ruggeri, A; Sestili, S; Vekhoff, A | 1 |
| Beelen, D; Bochtler, T; Brecht, A; Bunjes, D; Eder, M; Einsele, H; Kröger, N; Labopin, M; Labussière-Wallet, H; Mohty, M; Nagler, A; Niederwieser, D; Saraceni, F; Savani, BN; Tischer, J | 1 |
| Blaise, D; Bramanti, S; Calmels, B; Castagna, L; Chabannon, C; Charbonnier, A; Devillier, R; Faucher, C; Fürst, S; Granata, A; Harbi, S; Hospital, MA; Legrand, F; Lemarie, C; Lining, W; Maisano, V; Mokart, D; Pagliardini, T; Porta, MD; Rey, J; Saillard, C; Vey, N; Weiller, PJ | 1 |
| Czyż, A; Danylesko, I; Fein, JA; Nagler, A; Shem Tov, N; Shimoni, A; Shouval, R; Sobas, M; Vega, Y; Yerushalmi, R | 1 |
| Bednarski, JJ; Bhatt, ST; Hente, M; Murray, L; Schulz, G; Shenoy, S; Slater, A | 1 |
| Altman Kohl, S; Even-Or, E; Molho-Pessach, V; Stepensky, P; Zaidman, I | 1 |
| Briones, J; Brunet, S; Caballero, A; Esquirol, A; Garcia-Cadenas, I; Garrido, A; Granell, M; Martino, R; Moreno, C; Novelli, S; Querol, S; Saavedra, S; Sierra, J | 1 |
| Angelucci, E; Bacigalupo, A; Bregante, S; Bruno, B; Chiusolo, P; Grazia, CD; Grisariu, S; Iori, AP; Mordini, N; Olivieri, A; Patriarca, F; Raiola, AM; Rambaldi, A; Sica, S; Sora, F; Terruzzi, E | 1 |
| Bąbol-Pokora, K; Dąbrowska-Leonik, N; Frączkiewicz, J; Gul, K; Janeczko-Czarnecka, M; Kałwak, K; Martuszewski, A; Mielcarek-Siedziuk, M; Młynarski, W; Nowak, M; Paluszkiewicz, P; Salamonowicz-Bodzioch, M; Sierżęga-Staykov, K; Ussowicz, M; Wawrzyniak-Dzierżek, E; Wolska-Kuśnierz, B | 1 |
| Al-Chami, F; Angelucci, E; Bazarbachi, A; Bonifazi, F; Bruno, B; Carella, AM; Castagna, L; El-Cheikh, J; Iori, AP; La Nasa, G; Labopin, M; Mohty, M; Nagler, A; Santarone, S; Savani, B | 1 |
| Dandoy, CE; Davies, SM; El-Bietar, J; Grimley, MS; Khandelwal, P; Lane, A; Yeh, RF; Yu, L | 1 |
| Bertz, H; Duque-Afonso, J; Finke, J; Ihorst, G; Köhler, T; Marks, R; Müller-Quernheim, J; Wäsch, R; Waterhouse, M; Yücel, M; Zeiser, R | 1 |
| Barba, P; Bosch Vilaseca, A; Bosch, F; Esquirol, A; Fox, ML; García-Cadenas, I; Hernandez-Boluda, JC; Martino, R; Montoro, J; Ortí, G; Pérez, AM; Piñana, JL; Roldán, E; Saavedra, S; Salamero, O; Sanz, J; Sierra, J; Solano, C; Valcarcel, D; Villacampa, G | 1 |
| Banet, A; Battipaglia, G; Belhocine, R; Bianchessi, A; Bonnin, A; Boussaroque, A; Brissot, E; Duléry, R; Favale, F; Hirsch, P; Lapusan, S; Ledraa, T; Legrand, O; Malard, F; Médiavilla, C; Memoli, M; Mohty, M; Paviglianiti, A; Sestili, S; Van de Wyngaert, Z; Vekhoff, A | 1 |
| Angelucci, E; Bazarbachi, A; Berceanu, A; Blaise, D; Bulabois, CE; Ceballos, P; El Cheikh, J; Forcade, E; Kröger, N; Labopin, M; Mielke, S; Mohty, M; Nagler, A; Rambaldi, A; Savani, B; Socié, G; Spyridonidis, A; Yakoub-Agha, I | 1 |
| Kapoor, R; Rastogi, N; Yadav, SP | 1 |
| Aleinikova, O; Ansari, M; Ariffin, H; Bader, P; Balduzzi, A; Bierings, M; Buechner, J; Burkhardt, B; Corbacioglu, S; Dalle, JH; Diaz-de-Heredia, C; Essa, M; Güngör, T; Ifversen, M; Lankester, A; Locatelli, F; Meisel, R; Peters, C; Pichler, H; Poetschger, U; Schrappe, M; Schultz, K; Sedlacek, P; Shaw, PJ; Staciuk, R; Stein, J; Svec, P; Toporski, J; Truong, TH; Vettenranta, K; von Stackelberg, A | 1 |
| Angelucci, E; Arcese, W; Battipaglia, G; Blaise, D; Chalandon, Y; Chiusolo, P; Contentin, N; Czerw, T; de Wreede, LC; Fanin, R; Fox, ML; Hayden, P; Hernandez-Boluda, JC; Iori, AP; Kroger, N; Marotta, G; Mauff, K; McLornan, D; Mohty, M; Pioltelli, P; Rubio, MT; Santarone, S; Sever, M; Solano, C; Wendel, L; Yakoub-Agha, I | 1 |
| Bas, EG; Celen, S; Daloglu, H; Hazar, V; Kabakci, C; Karasu, GT; Pashayev, D; Pehlivan, B; Uygun, V; Yalcin, K; Yesilipek, A; Zhumatayev, S | 1 |
| Cuesta, M; Esquirol, A; Ferrà, C; Garcia-Cadenas, I; Herruzo, B; Martino, R; Pascual, MJ; Pérez, A; Sierra, J; Torio, A; Torrent, A | 1 |
| Aljurf, M; Angelucci, E; Arat, M; Bernasconi, P; Giebel, S; Labopin, M; Mohty, M; Nagler, A; Pavlu, J; Peric, Z; Pioltelli, P; Rigacci, L; Risitano, A; Rovira, M; Saccardi, R; Savani, BN; Sica, S; Socié, G; Spyridonidis, A; Swoboda, R; Tischer, J; Van Gorkom, G; Vitek, A | 1 |
| Arpinati, M; Baronciani, D; Bernasconi, P; Bonifazi, F; Brunello, L; Bruno, B; Busca, A; Carella, AM; Carluccio, P; Casini, M; Chiusolo, P; Ciceri, F; Cilloni, D; Cupri, A; Di Grazia, C; Gheorghiu, A; Giglio, F; Girmenia, C; Grassi, A; Grillo, G; Iori, AP; Luppi, M; Martino, M; Masciulli, A; Musso, M; Nozzoli, C; Oldani, E; Onida, F; Palazzo, G; Parma, M; Patriarca, F; Pavoni, C; Peccatori, J; Picardi, A; Proia, A; Rambaldi, A; Sacchi, N; Santarone, S; Sorasio, R; Tringali, S; Vacca, A; Vallisa, D | 1 |
| Abraham, A; Balasubramanian, P; Devasia, AJ; Fouzia, NA; George, B; Kavitha, ML; Korula, A; Kulkarni, UP; Lionel, S; Mathews, V; Pai, AA; Selvarajan, S; Sindhuvi, E; Srivastava, A | 1 |
| Bertz, H; Bornhäuser, M; Burchert, A; Dreger, P; Finke, J; Glass, B; Grishina, O; Hegenbart, U; Kobbe, G; Reicherts, C; Schmoor, C; Schub, N; Sohlbach, K; Stelljes, M; Wagner-Drouet, EM | 1 |
| Banet, A; Bazarbachi, A; Belhocine, R; Bonnin, A; Brissot, E; Duléry, R; El-Cheikh, J; Genthon, A; Labopin, M; Ledraa, T; Legrand, O; Malard, F; Memoli, M; Mohty, M; Sestili, S; Stocker, N; Van de Wyngaert, Z | 1 |
| Gale, RP; Halahleh, KA; Ma'koseh, M; Muradi, I; Rimawi, DH; Sultan, I | 1 |
| Cascio, E; Castillo, P; Farhadfar, N; Fort, J; Fraser, A; Horn, B; Lamba, J; Moore-Higgs, G; Slayton, W | 1 |
| Bagnoli, F; Barbullushi, K; Bellani, V; Cassanello, G; Cavallaro, F; Galassi, G; Goldaniga, M; Onida, F; Saporiti, G; Serpenti, F | 1 |
2 review(s) available for fludarabine and thiotepa
| Article | Year |
|---|---|
Nonablative hematopoietic cell transplantation for the treatment of metastatic renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Clinical Trials as Topic; Combined Modality Therapy; Cyclophosphamide; Cytokines; Graft Survival; Graft vs Host Disease; Graft vs Tumor Effect; Humans; Immunotherapy, Adoptive; Kidney Neoplasms; Melphalan; Multicenter Studies as Topic; Nephrectomy; Peripheral Blood Stem Cell Transplantation; Recombinant Proteins; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2002 |
[Dose adaptation of the drugs used for hematopoietic stem-cell transplantation in patients with comorbidity: Obesity, chronic renal disease or hepatopathy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-T
Topics: Adult; Age Factors; Busulfan; Child; Comorbidity; Cyclophosphamide; Etoposide; France; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Liver Diseases; Melphalan; Obesity; Renal Insufficiency, Chronic; Societies, Medical; Surveys and Questionnaires; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2017 |
21 trial(s) available for fludarabine and thiotepa
| Article | Year |
|---|---|
Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.
Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Child; Combined Modality Therapy; Graft Survival; Graft vs Host Disease; Haplotypes; Hematologic Neoplasms; Histocompatibility; Humans; Middle Aged; Peripheral Blood Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Failure; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2003 |
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Blood Transfusion; Female; Graft Survival; Hematologic Neoplasms; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Survival Analysis; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2004 |
A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphoma; Male; Middle Aged; Multiple Myeloma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Failure; Vidarabine | 2008 |
Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Drug Therapy, Combination; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine; Young Adult | 2008 |
Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT.
Topics: Adolescent; Adult; Antilymphocyte Serum; Child; Female; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Infections; Leukemia, Myeloid, Acute; Male; Melphalan; Middle Aged; Myeloablative Agonists; Myelodysplastic Syndromes; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2010 |
Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant.
Topics: Adolescent; Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Cord Blood Stem Cell Transplantation; Feasibility Studies; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Melphalan; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2012 |
T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome.
Topics: Adult; Antigens, CD34; Antilymphocyte Serum; Antineoplastic Agents; Disease-Free Survival; Ethnicity; Graft vs Host Disease; Histocompatibility Testing; HLA-C Antigens; Humans; Killer Cells, Natural; Leukemia, Myeloid; Lymphocyte Depletion; Middle Aged; Peripheral Blood Stem Cell Transplantation; Prospective Studies; Receptors, KIR; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine; Whole-Body Irradiation | 2012 |
Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen.
Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Graft Survival; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Myeloablative Agonists; Neoplasm Staging; Recovery of Function; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2012 |
Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cohort Studies; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Risk Factors; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2012 |
Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Agents; Bone Marrow Transplantation; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Follow-Up Studies; Graft vs Host Disease; Hematologic Neoplasms; Humans; Immunosuppressive Agents; Male; Middle Aged; Myeloablative Agonists; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2013 |
Treosulfan-fludarabine-thiotepa conditioning before allogeneic haemopoietic stem cell transplantation for patients with advanced lympho-proliferative disease. A single centre study.
Topics: Adult; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Disease-Free Survival; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Recurrence; Remission Induction; Salvage Therapy; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Transplantation, Homologous; Treatment Outcome; Vidarabine; Young Adult | 2016 |
Umbilical cord blood transplantation in adults with advanced hodgkin's disease: high incidence of post-transplant lymphoproliferative disease.
Topics: Acute Disease; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Female; Graft Survival; Graft vs Host Disease; Herpesvirus 4, Human; Hodgkin Disease; Humans; Infectious Mononucleosis; Male; Middle Aged; Myeloablative Agonists; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine | 2016 |
Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
Topics: Alemtuzumab; Anemia, Sickle Cell; Calcineurin Inhibitors; Child; Child, Preschool; Cord Blood Stem Cell Transplantation; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Hydroxyurea; Male; Melphalan; Mycophenolic Acid; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine | 2017 |
Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group.
Topics: Adult; Blood Donors; Busulfan; Female; Follow-Up Studies; Graft Survival; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Primary Myelofibrosis; Prognosis; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2019 |
Thiotepa, Busulfan, and Fludarabine Conditioning Regimen in T Cell-Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Cyclosporine; Disease-Free Survival; Female; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; HLA Antigens; Humans; Male; Middle Aged; Mycophenolic Acid; Retrospective Studies; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
Thiotepa, Fludarabine, and Busulfan Conditioning Regimen before T Cell-Replete Haploidentical Transplantation with Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia: A Bicentric Experience of 100 Patients.
Topics: Adult; Aged; Allografts; Busulfan; Chronic Disease; Cyclophosphamide; Disease-Free Survival; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Stem Cell Transplantation; Survival Rate; T-Lymphocytes; Thiotepa; Transplantation Conditioning; Vidarabine | 2019 |
A single-center experience using alemtuzumab, fludarabine, melphalan, and thiotepa as conditioning for transplantation in pediatric patients with chronic granulomatous disease.
Topics: Alemtuzumab; Child; Child, Preschool; Follow-Up Studies; Graft vs Host Disease; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Infant; Melphalan; Myeloablative Agonists; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Effect of the Thiotepa Dose in the TBF Conditioning Regimen in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission: A Report From the EBMT Acute Leukemia Working Party.
Topics: Adult; Aged; Allografts; Busulfan; Disease-Free Survival; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Total Body Irradiation or Chemotherapy Conditioning in Childhood ALL: A Multinational, Randomized, Noninferiority Phase III Study.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Chemoradiotherapy; Child; Child, Preschool; Equivalence Trials as Topic; Etoposide; Female; Follow-Up Studies; Humans; International Agencies; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Survival Rate; Thiotepa; Vidarabine; Whole-Body Irradiation | 2021 |
Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Prospective Studies; Recurrence; Thiotepa; Transplantation Conditioning; Vidarabine | 2022 |
Thiotepa-fludarabine-treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial.
Topics: Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Retrospective Studies; Thiotepa; Transplantation Conditioning; Unrelated Donors; Vidarabine | 2022 |
49 other study(ies) available for fludarabine and thiotepa
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Interaction of human organic anion transporter polypeptides 1B1 and 1B3 with antineoplastic compounds.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Humans; Liver-Specific Organic Anion Transporter 1; Molecular Structure; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Peptides; Solute Carrier Organic Anion Transporter Family Member 1B3 | 2015 |
Thiotepa and fludarabine (TT-FLUDA) as conditioning regimen in poor candidates for conventional allogeneic hemopoietic stem cell transplant.
Topics: Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Female; Graft Rejection; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Middle Aged; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2001 |
Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies.
Topics: Adult; Aged; Anemia, Refractory, with Excess of Blasts; Cyclophosphamide; Cyclosporine; Female; Graft vs Host Disease; Graft vs Tumor Effect; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Lymphocyte Transfusion; Lymphoma, Mantle-Cell; Male; Methotrexate; Middle Aged; Neoplasm, Residual; Polymerase Chain Reaction; Recurrence; Remission Induction; Survival Rate; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2002 |
Successful engraftment and stable full donor chimerism after myeloablation with thiotepa, fludarabine, and melphalan and CD34-selected peripheral allogeneic stem cell transplantation in hemophagocytic lymphohistiocytosis.
Topics: Antigens, CD34; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Graft Survival; Histiocytosis, Non-Langerhans-Cell; Humans; Infant; Melphalan; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Remission Induction; Thiotepa; Transplantation Chimera; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2003 |
High dose chemotherapy and autologous stem cell transplantation for poor risk and recurrent non-Hodgkin's lymphoma: a single-center experience of 50 patients.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Neoplasm Recurrence, Local; Retrospective Studies; Stem Cell Transplantation; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Autologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2004 |
Bone marrow mammaglobin expression as a marker of graft-versus-tumor effect after reduced-intensity allografting for advanced breast cancer.
Topics: Adult; Biomarkers, Tumor; Bone Marrow; Bone Marrow Neoplasms; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Gene Expression Regulation, Neoplastic; Graft Survival; Graft vs Tumor Effect; Humans; Mammaglobin A; Middle Aged; Myeloablative Agonists; Neoplasm Proteins; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Uteroglobin; Vidarabine | 2006 |
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma.
Topics: Adult; Aged; Disease-Free Survival; Female; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Myeloablative Agonists; Stem Cell Transplantation; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2007 |
Parvovirus B19 pneumonia in a child undergoing allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Combined Modality Therapy; Erythema Infectiosum; Fatal Outcome; Hematopoietic Stem Cell Transplantation; Humans; Male; Parvovirus B19, Human; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Radiography, Thoracic; Recurrence; Thiotepa; Tomography, X-Ray Computed; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2007 |
Salvage haploidentical transplantation for graft failure using reduced-intensity conditioning.
Topics: Adult; Animals; Antilymphocyte Serum; Carotid Arteries; Female; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Probability; Rabbits; Retrospective Studies; Salvage Therapy; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2012 |
New sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem-cell transplantation in very high-risk acute myeloid leukemia.
Topics: Adult; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Etoposide; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Stem Cell Transplantation; Survival Rate; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Therapeutic in vivo selection of thymic-derived natural T regulatory cells following non-myeloablative hematopoietic stem cell transplant for IPEX.
Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Bone Marrow Transplantation; Cell Survival; Forkhead Transcription Factors; Genetic Diseases, X-Linked; Graft Enhancement, Immunologic; Graft Survival; Humans; Immunologic Deficiency Syndromes; Infant; Interleukin-2 Receptor alpha Subunit; Lymphocyte Depletion; Male; Melphalan; Point Mutation; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Thiotepa; Thymus Gland; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2011 |
Radiation-free allogeneic conditioning with fludarabine, carmustine, and thiotepa for acute lymphoblastic leukemia and other hematologic malignancies necessitating enhanced central nervous system activity.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal, Humanized; Carmustine; Central Nervous System; Cyclosporine; Drug Administration Schedule; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2012 |
Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Topics: Adolescent; beta-Thalassemia; Busulfan; Child; Child, Preschool; Cyclosporine; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; India; Male; Myeloablative Agonists; Retrospective Studies; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2013 |
Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML.
Topics: Adult; Aged; Female; Follow-Up Studies; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myeloablative Agonists; Recurrence; Retrospective Studies; Stem Cell Transplantation; Thiotepa; Time Factors; Transplantation Conditioning; Vidarabine | 2013 |
Ex vivo T cell-depleted versus unmodified allografts in patients with acute myeloid leukemia in first complete remission.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Lymphocyte Depletion; Male; Melphalan; Middle Aged; Recurrence; Remission Induction; Retrospective Studies; Survival Analysis; T-Lymphocytes; Thiotepa; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2013 |
Unrelated CD3/CD19-depleted peripheral stem cell transplantation for Hurler syndrome.
Topics: Antigens, CD19; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Chimerism; Drug-Related Side Effects and Adverse Reactions; Female; Graft Rejection; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Lymphocyte Depletion; Male; Mucopolysaccharidosis I; Peripheral Blood Stem Cell Transplantation; Quality of Life; Survival Analysis; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2014 |
Bone marrow transplantation for non-malignant diseases using treosulfan-based conditioning.
Topics: Adolescent; Alkylating Agents; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cyclophosphamide; Disease-Free Survival; Female; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Myeloablative Agonists; Retrospective Studies; Thiotepa; Vidarabine | 2015 |
Severe infections after single umbilical cord blood transplantation in adults with or without the co-infusion of CD34+ cells from a third-party donor: results of a multicenter study from the Grupo Español de Trasplante Hematopoyético (GETH).
Topics: Adolescent; Adult; Antigens, CD34; Bacterial Infections; Busulfan; Cohort Studies; Cord Blood Stem Cell Transplantation; Cyclosporine; Female; Granulocyte Colony-Stimulating Factor; Humans; Immunosuppressive Agents; Leukemia; Lymphoma; Male; Middle Aged; Multivariate Analysis; Mycoses; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Risk Factors; Severity of Illness Index; Thiotepa; Transplantation Conditioning; Vidarabine; Virus Diseases; Whole-Body Irradiation; Young Adult | 2015 |
Permanent chemotherapy-induced nonscarring alopecia and premature ovarian failure.
Topics: Adult; Alopecia; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Female; Humans; Primary Ovarian Insufficiency; Thiotepa; Vidarabine | 2015 |
Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
Topics: Anemia, Diamond-Blackfan; Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Infant; Infant, Newborn; Male; Myeloablative Agonists; Thiotepa; Transplantation Conditioning; Treatment Outcome; Vidarabine | 2017 |
Adult Umbilical Cord Blood Transplantation Using Myeloablative Thiotepa, Total Body Irradiation, and Fludarabine Conditioning.
Topics: Adult; Aged; Cord Blood Stem Cell Transplantation; Female; Humans; Male; Middle Aged; Thiotepa; Vidarabine; Whole-Body Irradiation; Young Adult | 2017 |
Haploidentical hematopoietic stem cell transplant for patients with sickle cell disease using thiotepa, fludarabine, thymoglobulin, low dose cyclophosphamide, 200 cGy tbi and post transplant cyclophosphamide.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antilymphocyte Serum; Child; Cyclophosphamide; Female; Hematopoietic Stem Cell Transplantation; Humans; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Whole-Body Irradiation; Young Adult | 2018 |
Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia.
Topics: Adolescent; Adult; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; Combined Modality Therapy; Confidence Intervals; Cyclophosphamide; Disease-Free Survival; Drug Evaluation; Female; Graft vs Host Disease; Humans; Leukemia, Myeloid, Acute; Living Donors; Male; Middle Aged; Myeloablative Agonists; Peripheral Blood Stem Cell Transplantation; Proportional Hazards Models; Retrospective Studies; Siblings; Survival Analysis; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2018 |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation: an EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine.
Topics: Adult; Aged; Busulfan; Cord Blood Stem Cell Transplantation; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine; Young Adult | 2018 |
Immunosuppressive Total Nodal Irradiation-Based Reconditioning Regimens After Graft Rejection or Graft Failure in Pediatric Patients Treated With Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Topics: Adolescent; Allografts; Antilymphocyte Serum; Bone Marrow Transplantation; Child; Child, Preschool; Follow-Up Studies; Graft Rejection; Hematopoietic Stem Cell Transplantation; Humans; Immunologic Factors; Immunosuppression Therapy; Kaplan-Meier Estimate; Lymphatic Irradiation; Muromonab-CD3; Myeloablative Agonists; Radiotherapy Dosage; Retreatment; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
Fludarabine-treosulfan compared to thiotepa-busulfan-fludarabine or FLAMSA as conditioning regimen for patients with primary refractory or relapsed acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Europe; Female; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2019 |
Allogeneic hematopoietic stem cell transplantation with fludarabine, busulfan, and thiotepa conditioning is associated with favorable outcomes in myelofibrosis.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Skin toxicity following treosulfan-thiotepa-fludarabine-based conditioning regimen in non-malignant pediatric patients undergoing hematopoietic stem cell transplantation.
Topics: Busulfan; Child; Child, Preschool; Drug Eruptions; Drug Therapy, Combination; Female; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Prognosis; Prospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
When an HLA identical donor is not available in adults with hematological neoplasms: single-center comparison of single-unit cord blood transplantation and haploidentical-related PBSC transplantation with PTCy using a standardized conditioning platform (t
Topics: Adult; Aged; Allografts; Busulfan; Cord Blood Stem Cell Transplantation; Female; Hematologic Neoplasms; HLA Antigens; Humans; Male; Middle Aged; Peripheral Blood Stem Cell Transplantation; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Allogeneic Hemopoietic Stem Cell Transplants in Patients with Acute Myeloid Leukemia (AML) Prepared with Busulfan and Fludarabine (BUFLU) or Thiotepa, Busulfan, and Fludarabine (TBF): A Retrospective Study.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Successful Allogeneic Stem Cell Transplantation in Nuclear Factor-Kappa B Essential Modulator Deficiency Syndrome After Treosulfan-Based Conditioning: A Case Report.
Topics: Antilymphocyte Serum; Busulfan; Ectodermal Dysplasia; Hematopoietic Stem Cell Transplantation; Humans; I-kappa B Kinase; Immunologic Deficiency Syndromes; Infant; Male; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine | 2020 |
Graft-versus-host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft-versus-host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta-thalassemia Major With Busulfan, Fludarabine, and Thiotepa.
Topics: Abatacept; Adolescent; beta-Thalassemia; Busulfan; Calcineurin Inhibitors; Child; Child, Preschool; Drug Administration Schedule; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Infant; Male; Methylprednisolone; Retrospective Studies; Thiotepa; Time Factors; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2021 |
Comparison of reduced-toxicity conditioning protocols using fludarabine, melphalan combined with thiotepa or carmustine in allogeneic hematopoietic cell transplantation.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Hematopoietic Stem Cell Transplantation; Humans; Melphalan; Middle Aged; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Young Adult | 2021 |
Feasibility of thiotepa addition to the fludarabine-busulfan conditioning with tacrolimus/sirolimus as graft vs host disease prophylaxis.
Topics: Busulfan; Feasibility Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Retrospective Studies; Sirolimus; Tacrolimus; Thiotepa; Transplantation Conditioning; Vidarabine | 2020 |
Thiotepa-busulfan-fludarabine as a conditioning regimen for patients with myelofibrosis undergoing allogeneic hematopoietic transplantation: a single center experience.
Topics: Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Primary Myelofibrosis; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Comparable outcomes of haploidentical transplant with TBF conditioning versus matched unrelated donor with fludarabine/busulfan conditioning for acute myeloid leukemia.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Unrelated Donors; Vidarabine | 2021 |
Haploidentical Stem Cell Transplant With Post Transplant Cyclophosphamide for Chronic Granulomatous Disease With Thiotepa, Busulfan, and Fludarabine as Conditioning.
Topics: Antineoplastic Agents; Busulfan; Child, Preschool; Cyclophosphamide; Granulomatous Disease, Chronic; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Male; Thiotepa; Transplantation Conditioning; Transplantation, Haploidentical; Vidarabine | 2021 |
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neoplasms; Primary Myelofibrosis; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Comparison of Total Body Irradiation-based Versus Chemotherapy-based Conditionings for Early Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Children With ALL.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Etoposide; Female; Follow-Up Studies; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Infant; Male; Organophosphorus Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Retrospective Studies; Survival Rate; Thiotepa; Transplantation Conditioning; Transplantation, Homologous; Vidarabine; Whole-Body Irradiation | 2021 |
Combining Three Different Pretransplantation Scores Improves Predictive Value in Patients after Haploidentical Stem Cell Transplantation with Thiotepa, Busulfan, and Fludarabine Conditioning and Post-Transplantation Cyclophosphamide.
Topics: Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Thiotepa; Transplantation Conditioning; Vidarabine | 2021 |
Total body irradiation plus fludarabine versus thiotepa, busulfan plus fludarabine as a myeloablative conditioning for adults with acute lymphoblastic leukemia treated with haploidentical hematopoietic cell transplantation. A study by the Acute Leukemia W
Topics: Adult; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Whole-Body Irradiation | 2022 |
Endothelial Activation and Stress Index-Measured Pretransplantation Predicts Transplantation-Related Mortality in Patients with Thalassemia Major Undergoing Transplantation with Thiotepa, Treosulfan, and Fludarabine Conditioning.
Topics: Adolescent; Adult; beta-Thalassemia; Busulfan; Child; Child, Preschool; Female; Humans; Infant; Male; Retrospective Studies; Thiotepa; Vidarabine; Young Adult | 2022 |
Thiotepa, busulfan and fludarabine conditioning-regimen is a promising approach for older adult patients with acute lymphoblastic leukemia treated with allogeneic stem cell transplantation.
Topics: Adolescent; Adult; Aged; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Middle Aged; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine; Young Adult | 2023 |
High Incidences of Acute and Chronic Graft-Versus-Host Disease after Hematopoietic Cell Transplants for Acute Myeloid Leukemia Using Thiotepa, Busulfan, and Fludarabine Pretransplant Conditioning.
Topics: Bronchiolitis Obliterans Syndrome; Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Leukemia, Myeloid, Acute; Retrospective Studies; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |
Feasibility study of busulfan, fludarabine, and thiotepa conditioning regimen for allogeneic hematopoietic stemcell transplantationfor children and young adults with nonmalignant disorders.
Topics: Anemia, Sickle Cell; Busulfan; Child; Feasibility Studies; Hematopoietic Stem Cell Transplantation; Humans; Prospective Studies; Thiotepa | 2023 |
Treosulfan, thiotepa and fludarabine conditioning regimen prior to first allogeneic stem cell transplantation in acute myeloid leukemia and high-risk myelodysplastic syndromes: a single center experience.
Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Thiotepa; Transplantation Conditioning; Vidarabine | 2023 |